Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double Blind, Multicentric Phase III Trial Evaluating the Safety and Benefit of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer Who Remain Free of Disease After Receiving at Least 1 Year of Adjuvant Hormone Therapy

NCT01805271 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT01805271
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01805271 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double Blind, Multicentric Phase III Trial Evaluating the Safety and Benefit of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer Who Remain Free of Disease After Receiving at Least 1 Year of Adjuvant Hormone Therapy
Lead sponsor
UNICANCER
Phase
Phase 3
Overall status
Active, not recruiting
Start date
March 31, 2013
Completion date
June 30, 2030
Enrollment
1,278 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

primary non-metastatic breast cancer, who remain disease-free